3-Methyladenine (3-MA)

For research use only. Not for use in humans.

目录号:S2767 别名: NSC 66389 中文名称:3-甲基腺嘌呤

3-Methyladenine (3-MA) Chemical Structure

CAS No. 5142-23-4

3-Methyladenine (3-MA, NSC 66389) 是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用(加热助溶)

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的3-Methyladenine (3-MA)发表文献500篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA, NSC 66389) 是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用(加热助溶)
靶点
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵,这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡,这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高,就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比,在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D M3v1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTWe4VYO22P MV[ybC=> NYnyUHg4TE2VTx?= NH65dYZz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F NFm2bYszPTdzNkW2NS=>
A549  M{XzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorTN41O MlTJNog> NW\TNWljTE2VTx?= MUDy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E M3LFPVI2PzF4NU[x
95D NWjjb21wSXCxcITvd4l{KEG|c3H5 M{\i[FVuVQ>? MoTSNog> MmHPSG1UVw>? M3nw[4lvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= NFnpflEzPTdzNkW2NS=>
A549  NIHuOIFCeG:ydH;zbZMhSXO|YYm= NVi0N5JWPW2P NUjzRph[Omh? M3TmWmROW09? M4LCOolvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= NF3lVoszPTdzNkW2NS=>
NBL-W-S  MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rRflFuVQ>? MV22bC=> MlXK[Y5p[W6lZYOgS2FPXC14MTD0c5hq[2m2eR?= M1XHblI2OzJ|MkKy
NBL-W-S  NVPCT5FFSXCxcITvd4l{KEG|c3H5 MmLvNY1O M{m3[VZp MUTpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDHRW5VNTZz NE\mbZgzPTN{M{KyNi=>
A2780cp  NUfLb5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVexcW0> Mkf6NYg> MYnpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NYrjZmoxOjV|MkK2PVQ>
A549  NVzrZ|VUTnWwY4Tpc44hSXO|YYm= NInLeXo2dU1? M{\VT|Jp NVP1T246e3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK NEi1PXQzPTJ6NU[yPC=>
H157 Mn\qSpVv[3Srb36gRZN{[Xl? M3q2dVVuVQ>? MWWybC=> MWfzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= MnfUNlUzQDV4Mki=
MDR M1jhc2Fxd3C2b4Ppd{BCe3OjeR?= M2nCXFExdU1? NI\odm83cA>? MoDzd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N? NWLY[m9TOjVyMUm3NFE>
HT-29  NFLWb4pCeG:ydH;zbZMhSXO|YYm= NIfWVpcydU1? NFSwTmI1QGh? M{C2NmROW09? MUTlcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MnLoNlQ5PDJzNUi=
Microglia  M4fyN2Fxd3C2b4Ppd{BCe3OjeR?= MYG1cW0> MonNNlRp MV;k[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NXLKT3plOjR6MUi2NFE>
A2780cp NWS3d5lxSXCxcITvd4l{KEG|c3H5 NFrsW3czNjWvTR?= MkXVNYg> MkDZ[IRJOk9? NEewd45mdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp M2GxWlI1QDF5OUS2
HepG2 NYnQfoxTTnWwY4Tpc44hSXO|YYm= M1fuZVVuVQ>? NIfhe5Y1cA>? NFvTdW5qdmO{ZXHz[ZMhUExicnXs[YF{\Q>? MonENlQ4OTN3OEe=
A549 NYjISFlySXCxcITvd4l{KEG|c3H5 NWmyOHpFPW2P NVPNW4VFPDiq MUTk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK M3L0NFI1PzB4M{Cz
U2OS M3LuRWFxd3C2b4Ppd{BCe3OjeR?= MWOxNI1O MmW3NlRp Mk[zbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 NWSydlEyOjR4M{mwNVM>
Saos-2 NEXNepBCeG:ydH;zbZMhSXO|YYm= NFfNflkyOG2P NIHWW3QzPGh? MlvXbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 NYPVfHFSOjR4M{mwNVM>
A549 NXrU[VYySXCxcITvd4l{KEG|c3H5 MUmxNI1O M4n1OlQ5cA>? NVn2O246[WOlZXzldoF1\XNidHjlJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KFCWWB?= M3i4VlI1PjJ4N{Ky
HCT116  M3LOcWFxd3C2b4Ppd{BCe3OjeR?= NYrsRlFQPW2P MYiyOIg> NYTTSYh1\W6qYX7j[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIFxcWenbnnu MojRNlQ3OjZ3MkK=
HGC-27 MlXRSpVv[3Srb36gRZN{[Xl? Mk\mNVBuVQ>? M1vkU|Fp MlrHbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= M1nU[|I1PDF4M{S5
U2OS  MVfGeY5kfGmxbjDBd5NigQ>? NXLWN3hpOC53L{HtUS=> NHPmd201QGh? M4e3O4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ M3Ho[|I1OzV6M{Sy
MG-63 NXfSW|l{TnWwY4Tpc44hSXO|YYm= MVywMlUwOW2P NGLqRpY1QGh? M4HIRYlv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ Ml7UNlQ{PTh|NEK=
MG-63 MoS2RZBweHSxc3nzJGF{e2G7 M3HzNVAvPS9zbV2= M{nXclMzcA>? Mn\E[Y5p[W6lZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= M13ucFI1OzV6M{Sy
MG-63 NGXNfIxCeG:ydH;zbZMhSXO|YYm= MkeyNVBuVQ>? NHf3NZkyOmh? M1LBXYVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ NUTl[WJkOjR|NUizNFE>
NTUB1 MlK1RZBweHSxc3nzJGF{e2G7 Mmr4OY1O NFfveWIyNjWq NYO5S4NzeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| NFOyeVUzPDN2OUG3Oi=>
T24 MWrBdI9xfG:|aYOgRZN{[Xl? NHzXVWE2dU1? MoXGNU42cA>? NX\GRnlDeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| MkXFNlQ{PDlzN{[=
SGC-7901  NGfnUpZCeG:ydH;zbZMhSXO|YYm= MWqycW0> MkP3NYg> M1nRVIlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| MV[yOFMzOTN2MB?=
SMMC-7721 NFHkc4dCeG:ydH;zbZMhSXO|YYm= NHnFNY0zdU1? MV2xbC=> M3nxTIlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| NH;rXowzPDN{MUO0NC=>
ECSCs  MoDqRZBweHSxc3nzJGF{e2G7 MlnpNVBuVQ>? NHLMcJg1cA>? M{f6doRm[3KnYYPld{Bz[XCjbYnjbY4ufHKnYYTl[EBieG:ydH;zbZM> M3y5TlI1OzF7MUC5
MCF-7  Mnr4SpVv[3Srb36gRZN{[Xl? MoThNVBuVQ>? NG\OUlMzPGh? M1GwfolvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= NUC5S2FnOjR|MUW1O|g>
UOK257 NYnHRmNsSXCxcITvd4l{KEG|c3H5 NH7ibow2dU1? M1i5SFNp M{X6VIVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MmLtNlQ{ODV4MES=
ACHN-5968 NYfzbHRCSXCxcITvd4l{KEG|c3H5 MnnJOY1O NW\hWZY6O2h? M4XyRYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? M1yxUFI1OzB3NkC0
Huh7 MVnBdI9xfG:|aYOgRZN{[Xl? NHHUc4MzdU1? MlfhNVJp NHzoNmdFVVOR MXTpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= M33NPFI1Ojl5M{Cw
Hep3B M4r0SmFxd3C2b4Ppd{BCe3OjeR?= NHrvPXQzdU1? NVvNNpJvOTKq M2e5TWROW09? M{jkfolvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo MXqyOFI6PzNyMB?=
RKO M1vENGZ2dmO2aX;uJGF{e2G7 MYeycW0> MlfmNYg> MY\EUXNQ NYnGeI1l\W6qYX7j[ZMh[2WubDDk[YF1cCCkeTDn[Yxl[W6jbYnjbY4> M{n2OFI1OjlzN{e3
HepG2 E47 NV7v[I1MTnWwY4Tpc44hSXO|YYm= MXmyMlVuVQ>? M175blQ5cA>? NEPlTWZqdmO{ZXHz[ZMhfGinIITvfIlkcXS7IH;mJGFCNCCEU1:sJIFv\CCFQ3y0 NGXGb2ozPDJ5M{ezPC=>
LoVo  M{fyemFxd3C2b4Ppd{BCe3OjeR?= M4Tue|VuVQ>? MWK0PIg> MoHV[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? MXiyOFIxOThzMh?=
WiDr MWHGeY5kfGmxbjDBd5NigQ>? NIf5VpQyOG2P M4T4SFFp M{jzNolvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? MknFNlQyQTB2OEm=
H1299  NYPxVohjTnWwY4Tpc44hSXO|YYm= MlnuNVBuVQ>? MX60bC=> MoDxbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NUjmfXZyOjRzN{OyNFg>
H460 NHrLTVRHfW6ldHnvckBCe3OjeR?= NEDGNpEyOG2P M2fkR|Rp MXLpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NWDvXW1pOjRzN{OyNFg>
A549 MVnGeY5kfGmxbjDBd5NigQ>? NV;F[VByOTCvTR?= MlPVOIg> NIi1fItqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCrcoLh[IlifGmxbh?= NHjDT|kzPDF2MkezOS=>
Hep3B MmT3RZBweHSxc3nzJGF{e2G7 MkfZOY1O NVnpZ2U4OjSq NHvJ[YJifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> NEDxdIQzPDB4Nk[5Ny=>
SMMC-7721 M1;EOGFxd3C2b4Ppd{BCe3OjeR?= M3i4UVVuVQ>? NFLEUW4zPGh? MXLheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= M3;2ZlI1ODZ4Nkmz
HO8910 M1HCXmFxd3C2b4Ppd{BCe3OjeR?= M2XvfFExdU1? NGHGWYsyOmh? NXfIPJRy\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? M1zWVlI{QTh|NkGw
MCF7 NHvnbHFHfW6ldHnvckBCe3OjeR?= NFnOc482dU1? NFjzNm8zPGh? NFH3co9qdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= Mm\6NlM6PjJ4Mkm=
HONE-1  NV;sN4pJTnWwY4Tpc44hSXO|YYm= NXqzeVZsPW2P M4j3SFFp NXT3eFdXemWycnXzd4V{KD[{LX3l[IlifGWmIGLPV{Bxem:mdXP0bY9v NIrpOWYzOzh7MkO1PC=>
HeLa NUPzfng4TnWwY4Tpc44hSXO|YYm= MX2xNI1O NVrOSnNZOmh? MWjzeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> NHrmVZYzOzh4NEezPC=>
HepG2 M3vufWZ2dmO2aX;uJGF{e2G7 MXexNI1O Mn7WNlRp MXzpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= NUDNSYNjOjN6MUewOFA>
SH-SY5Y MYnGeY5kfGmxbjDBd5NigQ>? MlXxNY1O NVTqeXpnOjSq MYDpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> MnS4NlM4PDNzNEi=
SH-SY5Y NVS0Z|VSSXCxcITvd4l{KEG|c3H5 NGrlTJg2dU1? M1S1bFFp MWHhZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? NVjwb4Q4OjN4MUmzPVU>
PC12  NILWTJpHfW6ldHnvckBCe3OjeR?= NHzZcJkyOG2P NFXqNnIzPGh? NFrrNop4[XSnch?= MnrvxsBqdmirYnn0d{BkcHmvb4TyfZB{cW5vbHnr[UBxem:2ZXHzc41idCCjY4Tpeol1gS5? NGPFSZAzOzZyM{m3PS=>
OV2008 MVvBdI9xfG:|aYOgRZN{[Xl? MV61cW0> NEK4d|QzPGh? MmrjZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? Mo\LNlM2QTJ{OEG=
A2780 NHfySXRCeG:ydH;zbZMhSXO|YYm= MVi1cW0> MV[yOIg> M3\FcYNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| NHK5S28zOzV7MkK4NS=>
Saos-2  NGnt[IJCeG:ydH;zbZMhSXO|YYm= NU\qXYVuOW2P MlLCPVZp MkKzbY5kemWjc3XzJINmdGxiZHXheIghcW6mdXPl[EBjgSCSQ2i= MUOyN|U3OzF5MR?=
1321N1 M3PNSWN6fG:2b4jpZ4l1gSCDc4PhfS=> NHS4ZZE2dU1? MlPnNlRp Ml3YdJJwfGWldIOgZ4VtdCCjZ3HpcpN1KFCFTj3pcoR2[2WmIITvfIlkcXS7 MlfXNlM2OjV{NkW=
SH-SY5Y MXPDfZRwfG:6aXPpeJkhSXO|YYm= NGnUSpM2dU1? M3j6OFI1cA>? NHX2fFZqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NGrtcFEzOzV{NUK2OS=>
HT-29  MV;GeY5kfGmxbjDBd5NigQ>? MX:xcW0> NV\lUnhmPDhxOU\o NVrqNodrcW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> M{XEZVI{PTB6Mkey
OR6 MXTGeY5kfGmxbjDBd5NigQ>? NIPhT20yOG2P MmnNO|Jp NXHSRoZPe3WycILld5NmeyCKQ2[gdoVxdGmlYYTpc44h[W6mIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= M1rlRlI{Ozl3OEe1
Hela  MXLGeY5kfGmxbjDBd5NigQ>? NFzJcJg2dU1? MU[yOIg> MoTMbY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> M1e3OVI{Ozl3Nke5
MCF-7  NGXGPGdHfW6ldHnvckBCe3OjeR?= MW[1cW0> MYWyOIg> M3\kSolvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NXnXbotMOjN|OUW2O|k>
HUVECs Mn22SpVv[3Srb36gRZN{[Xl? NIHYRpY{dU1? NYPxfoRwOjSq MlfsZoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? M2S5eVI{OzV6OUK4
T24 NELOSmhHfW6ldHnvckBCe3OjeR?= M2jaWlExdU1? NE\yb4wycA>? NGmyeYZz\WS3Y3XzJJRp\SClbHXheoFo\SCxZjDMR|Mh[W[2ZYKgZoFq[2GuaX6geJJm[XSvZX70 M4LwUlI{OzV2MEiw
U251MG  NGfYWYpHfW6ldHnvckBCe3OjeR?= MVmzcW0> MkK0NYg> MYTzeZBxemW|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36= MYOyN|M{QDZzOB?=
GTL-16  NEK2XZdCeG:ydH;zbZMhSXO|YYm= M3zx[FVuVQ>? NEOwNpEzPGh? NFPvZWJz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHzJINwdXCjcnXkJJRwKGOnbHzzJJRz\WG2ZXSge4l1cCCPRWSgbY5pcWKrdH;ydy=> NWDzTFVxOjN|MUO0PVA>
T-47D M13oTGZ2dmO2aX;uJGF{e2G7 NV\C[WF6OTCvTR?= NHPzNpMzcA>? NILa[mVqdmirYnn0d{BifXSxcHjh[5kheHKxY3Xzd{BidmRiaX7jdoVie2W|IILhdIFugWOrbjDpcoR2[2WmIHHwc5B1d3Orcx?= NVjweY5COjN|MECwNlY>
PaCa44 Mo\ZRZBweHSxc3nzJGF{e2G7 NV\zXFVCOi53bV2= Mon1NYg> M{HLbpJm\HWlZYRCpIdmdmmyaX6tcYVlcWG2ZXSgZZBweHSxc3nz MnPENlMyOjRzMUK=
MDA-MB231 NF[xR2dHfW6ldHnvckBCe3OjeR?= MYW1cW0> NWfxdYxHOWh? NFTwcJhqdmO{ZXHz[ZMhemW|dnXyZZRzd2xvbXXkbYF1\WRiY3HzdIF{\SCjY4TpeoF1cW:wIHHu[EBk\WyuIHTlZZRp NIjwVm0zOzB6OEi1NC=>
HeLa M3zleWFxd3C2b4Ppd{BCe3OjeR?= NYfvdJpDOTCvTR?= MkP6Nog> M4rDeYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> NIH6fIozOzByMEGzOS=>
SK-HEP-1 NXK4ZokxSXCxcITvd4l{KEG|c3H5 NXfRWHBROTCvTR?= NInZRVkycA>? MmfVdJJwfGWldIOgZYdicW6|dDDheZRweGijZ4mgZY5lKGmwZIXj[ZMh[XCxcITvd4l{KGmwIHL1[oFtcW5vdILlZZRm\CClZXzsdy=> MmO4NlI5PTh4NEm=
HepG2 NFToPFhCeG:ydH;zbZMhSXO|YYm= M4P2e|NuVQ>? MlHCOYg> MXjy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliUVTz M37pbFIzQDN4NUm1
MCF-7  NHrlPI1HfW6ldHnvckBCe3OjeR?= MYCycW0> MVqyOIg> NU[2O2VrcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NHy0bW8zPDl5ME[3Oi=>
MDA-MB-231 M3;TRmZ2dmO2aX;uJGF{e2G7 NU\Wb45IOm2P NWDSWGI1OjSq NVnldXRbcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> Mn[4NlQ6PzB4N{[=
MCF-7  NFHk[lJHfW6ldHnvckBCe3OjeR?= MXGycW0> NF7wZog1QGh? NIPHe3Nxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NWjvW3k1OjR7N{C2O|Y>
MDA-MB-231 M2jURWZ2dmO2aX;uJGF{e2G7 NUHtNmJIOm2P M3P2VVQ5cA>? NWDYfVBteHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq NIO0[2IzPDl5ME[3Oi=>
PANC-1  NILkR|VCeG:ydH;zbZMhSXO|YYm= M2fufVFuVQ>? MWC0PIg> MWXEUXNQ M3zkdYVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ MV:yOFg1OjF3OB?=
MDA-MB 231 NVfYUYFQSXCxcITvd4l{KEG|c3H5 NYX4ZZBVPW2P MlfvNE42cA>? MYTtc4R2dGG2ZYOgWI9kd22rbtMuxsBqdmS3Y3XkJIFxd3C2b4Ppdy=> NE\ibZgzPDh|MEe4NS=>
Microglia  NX3VUmZwSXCxcITvd4l{KEG|c3H5 MljvOY1O NVXIfIFrOjSq NVLDbFFH\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRp NVvUc5Z6OjR6MUi2NFE>
A2780cp M4fqZmFxd3C2b4Ppd{BCe3OjeR?= NIj5ZmgzNjWvTR?= M2\6[|Fp NVrIeXI6\GSKMl:= Mo\F[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NHfFZ4YzPDhzN{m0Oi=>
HepG2 MV;GeY5kfGmxbjDBd5NigQ>? MY[1cW0> NEHGdGw1cA>? NHTsVo5qdmO{ZXHz[ZMh[2WubIXsZZIhdGW4ZXzzJI9nKEiOwrC= MofTNlQ4OTN3OEe=
U2OS Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNI1O NF[3WpgzPGh? NEG0epZqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUBFd3h? M1XvNFI1PjN7MEGz
HCT116 Ml7ERZBweHSxc3nzJGF{e2G7 NXXDb49pPW2P NUfRdIR3OjSq NFLoOpNFVVOR MWXlcohidmOnczDhdIlo\W6rbj3pcoR2[2WmIHPlcIwh\GWjdHi= NELoUHkzPDZ{NkWyNi=>
MCF-7  MW\BdI9xfG:|aYOgRZN{[Xl? MljWNE4ydU1? NVzoUINrPmh? MknM[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:|aYO= M4TGOFIzPzVzOUi5
PC-3  Mn;oRZBweHSxc3nzJGF{e2G7 NHPNV28zdU1? M{S0SFJp MYXpcoNz\WG|ZYOgU3JKNWmwZIXj[YQh[2WubDDk[YF1cA>? MXWyNlc1PTV6MB?=
U251  MXfBdI9xfG:|aYOgRZN{[Xl? NV7zWW5qPW2P MkHoNlRp Ml[1bY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? MVWyNlU4QTd6OB?=
HeLa  MmrhRZBweHSxc3nzJGF{e2G7 M1W4TlVuVQ>? NWLzR2U6OjSq MoqwbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDj[YxtKGSnYYTo MXGyNlU1PTF{OB?=
A549 MlLWSpVv[3Srb36gRZN{[Xl? Mnn1NE4ydU1? M3fFU|I1cA>? MUTzeZBxemW|c3XzJHNWOTF{N{StbY5lfWOnZDDj[YxtKGSnYYTo NH;Pco4zOjR4Nkm2NC=>
pDCs MlH5SpVv[3Srb36gRZN{[Xl? MojoNVBuVQ>? MYmwMlVp MkO5xsBz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gTWZPNc7zIHL5JJN{Wk6DNEC= MlLRNlI{QTZ3OUm=
BGC-823 NU\WZYk3TnWwY4Tpc44hSXO|YYm= NFS2VY42dU1? MV2ybC=> M37odYlvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> MXqyNlMzOjF3Mh?=
U937 M4j2[mZ2dmO2aX;uJGF{e2G7 NUH6R4tlOm2P MmTSNVJp M4HBUYRm[3KnYYPld{B1cGViYYX0c5Bp[We7IILheIlwyqB? Ml\mNlIyPTVzNUC=
Marc-145 NIHCdmlHfW6ldHnvckBCe3OjeR?= M17GNVVuVQ>? M3KxTVEzNzJ2L{O2bC=> M1Tte5Jm\HWlZYOgeIhmKFCUUmPWJJRqfGW{czDhcoQhfGinIIDyc5RmcW5iZYjwdoV{e2mxbh?= M1SwcVIzOTF7OUCw
HBx  NYTw[nFsSXCxcITvd4l{KEG|c3H5 MWmxNI1O NI\wUHo1QGh? Mlf2SG1UVw>? NGHs[3JqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? NVzVVWVCOjJyMkCwO|g>
MCF-7 Ml3mSpVv[3Srb36gRZN{[Xl? M2mzSlExdU1? M3jWWlQ5cA>? M3LKZoJtd2OtczDheZRweGijZ4mgbY5lfWOnZDDifUBjd3K2ZYrvcYlj Ml7INlE6OzF7M{e=
RMPI8226  NV\YPFU4TnWwY4Tpc44hSXO|YYm= M1XBcFVuVQ>? M3;sXlFp MmXwd5VxeHKnc4Pld{B1cGVibHX2[Ywhd2ZiYYX0c5Bp[We7IIXu[IVzKG63dILp[Y51KGSncHzleIlwdg>? MUmyNVkyPTZ{MB?=
PC12/TetOn NWHid2J3TnWwY4Tpc44hSXO|YYm= MV:wMlEwOW2P NETDWI8yQGh? NX3vOoJ{dGWjZIOgeI8h|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC= M4nOSFIyQTB4NkW5
HeLa  MXjDfZRwfG:6aXPpeJkhSXO|YYm= NELRXIIzdU1? NV\3dVJMOjSq Ml;WbY5pcWKrdHXzJJRp\SCleYTveI95cWOrdImgc4Yhe2muaXLpcolvKHSxIFjlUIEh[2WubIOu M3fEUVIyQDd3M{i1
Jurkat MVLGeY5kfGmxbjDBd5NigQ>? MlXPNVBuVQ>? Mn;xNYg> NIO1dWdl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MlOyNlE5PjRyM{e=
K562 MWfGeY5kfGmxbjDBd5NigQ>? NYTVWXBvOTCvTR?= MVqxbC=> MV3k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MW[yNVg3PDB|Nx?=
Nara-H MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3rOY1O MXS0PIg> NYLCc4Rv\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> NUj4PWN5OjF6MEWwN|M>
HUVECs NVvwTIU1TnWwY4Tpc44hSXO|YYm= MlPjNVBuVQ>? MkKxNE42cA>? MXTk[YNz\WG|ZYOgeIhmKEGJRT3CV2FqdmS3Y3XkJIF2fG:yaHHnfUBt\X[n Mmr4NlE1Pjh3OUK=
HepG2 M1vONWFxd3C2b4Ppd{BCe3OjeR?= MWqycW0> MV:xbC=> M2\zW4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> M1TyelIyPDV|Nkmx

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调,与此一致的是与SAH + 对照成分组相比,SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[4]
- 合并

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验:[2]
- 合并
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率(如HeLa细胞)。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬,密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5

CAS号 5142-23-4
储存条件 粉状
溶于溶剂
别名 NSC 66389

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID